Search results

Ilonov develops first-in-class biotherapies unlocking the muscle secretome to counter metabolic dysfunction. Our lead assets, based on human-centric discovery, preserve mitochondrial health, maintain tissue function and reduce chronic inflammation, addressing the unmet need in diabetes and MASH.

RhyGaze is a cutting-edge biotechnology company based in Basel, Switzerland, and Philadelphia, Pa., USA, focused on developing gene therapies for retinal diseases causing blindness and aims to restore vision and transform the lives of patients worldwide.

Headquartered in Switzerland with global operations, Space Peptides provides end-to-end pharmaceutical Peptide CRDMO services - covering discovery, process development, and GMP manufacturing. In addition, our portfolio comprises a broad range of generic Peptide APIs.

AzureCell is a Swiss regenerative cell therapy company leveraging two decades of pioneering neuroscience and cell‑engineering research at the University of Geneva to advance next‑generation allogeneic cell‑replacement therapies for the brain.

Streamlining complexity: with 15+ years experience (EU, US and Far East) in Oncology, Rare Diseases and Quality of Life Assessment, Naexture provides ad-interim leadership roles in Clinical Operations and Program Management to end-to-end operationalize clinical research programs.

Stallergenes Greer is a fully integrated global healthcare company specialising in the research, diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy (AIT) products and services.

CALDRE is a Switzerland based biotech spin-out focussed to revolutionize the way cholestatic-and fibrotic diseases are treated. We develop precise, liver-directed GalNAc-siRNAs to restore bile flow and prevent fibrosis - placing CALDRE in the fast-growing RNA-therapeutics segment of biotech.

Almac provides the most comprehensive global clinical supply chain solution in the marketplace. Guided by our extensive supply experience, we provide the physical resources and supportive technologies that ensure your clinical supply chain continually delivers across the globe.

SYDRA AG (Zurich) is a longevity biotech using a phenotype-first, AI-assisted “Hit-to-Target” early drug discovery platform. We discover small molecules (geroprotectors), validate in vivo (worms – aged mice), then map MoA to build partner-ready drug assets; plus science-backed supplements.

Jantar is a clinical R&D company in the field of chronic rhinosinusitis. Its product is a nasal spray of dicholine succinate. Clinical efficacy has been demonstrated by well-documented case studies which showed that the drug relieves all symptoms of the disease. A PCT patent has been filed.

Mabylon is a clinical-stage company leading innovation in human-derived antibody therapeutics for severe allergies, inflammation, and neurological disorders. MY006, our first-in-class multi-specific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.

As a health company, we envision empowering global well-being by pioneering biological solutions drawn from nature. Our mission: Unlock the full potential of exDNA across diverse indications. Our AND Technology Platform has the primary focus on controlling disease caused by pathogenic bacteria.

Ultimate Medicine is a Swiss preclinical biotech focused on preserving independence and quality of life for patients with Alzheimer's disease and other dementias.

TheraPPI Bioscience, a preclinical biotechnology company developing small molecules modifying protein interactions in oncology, rare diseases and inflammation

Tridek-One is a biotech start-up developing first-in-class CD31 agonist modalities designed to restore the immune balance.

A swiss-based company developing therapeutics for chronic inflammation. We are engineering novel bi-functional Duokine therapeutics, rationally designed to simultaneously target distinct immune cell populations and disease-relevant pathways.

metaLead is an early-stage life science spinout from the University of Zurich, supported by reputable investors, i.e., BaseLaunch. We aim to revolutionize the treatment landscape for metal-related diseases, starting with Wilson disease, leveraging our platform of novel, rationally designed peptides.

Leman Biotech is a clinical-stage biotech advancing immunotherapy via metabolic reprogramming. Its META 10 platform reverses T-cell exhaustion to unlock unprecedented efficacy and durability in oncology and autoimmune diseases, delivering a highly effective, scalable, and accessible approach.

Abbmira therapeutics is a Basel based biotech founded by experience scientists and entrepreneurs in September 2024. Abbmira develops first-in-class small molecules to fine-tune native immunity to treat difficult-to-treat cancers and chronic diseases.

InVirtuoLabs is pioneering the next-generation laboratory by integrating AI with molecular simulations to revolutionize drug discovery. Our platform generates up to 1 billion novel molecules per day, rapidly screening and identifying the most promising ligands for specific biological targets.

Avenza Consulting has been created to support pharma, biotech companies, startups to develop and grow by offering Strategic Consulting, R&D services to foster innovation, Program & Portfolio Management to optimize projects, and Operational Excellence to streamline processes.

Juvion develops advanced therapeutics aimed at preserving neuron-muscle connectivity, tackling immobility and sarcopenia to extend healthspan.

Enzene is a fully integrated CIDMO with sites in Pune (India) & New Jersey (USA), offering discovery to commercial supply. Its EnzeneX™ FCCM™ tech leads next-gen biologics, aiming to cut mAb costs below $40/g by 2025. Learn more at www.enzene.com.

BeOne Medicines is a global oncology company developing innovative, affordable, and accessible cancer treatments worldwide. We expedite development of our diverse pipeline of novel therapeutics through strong internal capabilities and collaborations. Our 11,000 colleagues span six continents.

Justin Stindt Consultants is a consulting firm specializing in Strategy & Market Access advisory services for the pharmaceutical, biotech and medical device industries.

We are offering worldwide professional medical writing and related services to the pharmaceutical (human & veterinary), biotech, medical device and other industries, CROs and academic institutions. With over 20 years of experience in the field, we guarantee the best possible medical writing.

Founded in mid-2022, T-Oncology is a Swiss biotech startup dedicated to transforming cancer treatment through innovative therapies. Our Mission: Give hope to patients by creating advanced therapeutics that offer safe and more effective treatment options, affordable for patients worldwide.

Amporin is developing a new class of small molecule amyloid pore inhibitors as the first potential acute oral drugs to stop and reverse the progression of deadly degenerative diseases. Our vision is to cure 6 major degenerative diseases with a simple pill, starting with Parkinson’s disease.

Access2Health partners with biotechs, providing flexible, cost-effective support to maximise asset value. We offer strategic guidance in market potential, evidence generation, pricing, and value strategy, helping biotech leaders make informed decisions that strengthen their position with investors.

ICE Biopharma has 2 core businesses: in-licensing specialty and rare disease drugs for Europe and Canada, and operational consultancy to companies evaluating international Commercialization options. We want European and Canadian patients to have access to the breakthrough therapies they deserve.

Allegria Therapeutics was founded in Basel in 2023. Pursuing a differentiated portfolio of proprietary therapeutic approaches around biological targets that selectively modulate mast cells, Allegria plans to redefine the treatment landscape for allergy and mast cell-mediated inflammatory diseases.

Complyomics supports Life Sciences companies in core areas as: Build and maintain robust Quality Systems in compliance with regulatory requirements. Provide externalized QA. Audits Develop expertise in Bioanalytical / Analytical areas Identify / assess / supervise sub-contractors Due diligence

Tandem Therapeutics (Spin-off ETH Zurich & PSI) is tackling the growing unmet medical need in treating fibrosis with precision extracellular matrix targeting. Our novel peptide drug conjugates selectively target mechanical changes in the fibrotic extracellular matrix to potentially halt progression.

HekeTiss, a UNIGE/HUG spin-off, enhances lives by pioneering cell-therapy treatments for ulcerative skin conditions. Innovating for a healthier tomorrow.

Luminance Health is a premium life science consultancy providing personalized support across the entire value chain. We provide cross-functional strategic and hands-on support to develop, register, market and bring innovative products to market.

Curie.Bio is a $1.2B VC founded to discover and develop important new medicines. We do that by investing directly into existing companies, creating focused spinouts, and helping founders build companies from scratch. Our team of >80 full-time drug hunters provides hands on support to founders.

At Stämm we develop accessible, plug & play biomanufacture solutions; allowing an automatized, continuous and more efficient production of biologics and cell therapies while managing media conditions. We have reinvented biomanufacturing by providing an alternative to the known biomass production.

Bavarian Nordic is a fully integrated vaccine company focused on the development, manufacturing and commercialization of life-saving vaccines. Our manufacturing site for oral vaccines is located in Thörishaus, 15 km southwest of Bern.

Altorfer Engineering is a specialized contractor and consulting company. We provide expertise in engineering and project management services, and technology transfers. Our focus is on developing and managing aseptic formulation and fill-finish processes tailored to your receiving sites.

Blueprint Medicines is a global precision therapy company inventing life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, our medicines selectively target genetic drivers, with the goal of staying one step ahead of disease.

Infinity Communications works with start-up and growth-stage healthcare companies to deliver insights-driven, strategic communications. We add value by developing content and material to raise your company profile, attract new investors and engage audience groups across the health ecosystem.

Curare specializes in translational and clinical pharmacology, increasing confidence in therapeutics translation from the bench to clinical proof of concept, and enhancing early stage decision-making.Expertise tailored to your needs, from small biotech to pharma.

MRGN Advisors was established in 2015 to advise CEOs, boards and investors on portfolio strategy, commercial and market access development, partnering and investment advisory in pharma, biologicals, vaccines, med tech and healthcare IT. Our motto: Even monkeys fall from trees — Japanese Proverb

Our goal is to deliver innovations in health care through cutting-edge tech and research, addressing challenges in antimicrobial therapies to improve patient outcomes. We are committed to delivering superior treatments that promote healing and improve quality of life globally.

I work WITH my clients as a freelance science business development project manager. Having said that, Boehler Life Science Advice is not typical consultancy, even though strategic planning and execution is an important part of supporting my clients.

VACCENTIS AG is a Zurich-based investment company focused on the biotech and pharmaceutical sector. The entire research, production and sales activities are carried out by two highly specialized subsidiaries, VCC MEDICAL and FBM- Pharma, which focus on special methods of personalized medicine

InkVivo Technologies combines its patented biomaterial platform with advanced manufacturing technologies to fabricate novel delivery systems that ensure controlled and prolonged release of active ingredients (e.g., small molecules, biologics and micronutrients).

Provectis Healthcare AG is a global healthcare company based in Basel and the commercial partner of choice to the innovative biopharma. We advance the innovation through launch, commercialization and brand building in Europe, Middle East and Asia.

Amphilix AG is a Basel-based biotech developing next-generation radioligand therapies using a proprietary 3D linker platform and small-molecule ligands. Its clinical-stage lead AMX-0053 targets a protein for colorectal cancer and is ready for First-in-Human imaging. The company seeks CHF 9m Seed.

Toxicology Consultant with >25 years of experience in the Biopharmaceutical Industry. I support Startup and Biotech Companies to advance their projects into the clinical phase. Get in touch to discuss your project when you have a shortage of nonclinical and toxicological expertise.

Cellerys AG is a clinical stage biotechnology company, developing immune tolerance therapeutics for the treatment of multiple sclerosis (MS). Antigenic peptides identified from MS patients are coupled to autologous red blood cells which, when reinfused, restore immune tolerance. in 2021 the company entered a

MEDICE has always developed and produced medicinal products almost exclusively at the Iserlohn site and concentrates in the prescription area on CNS, renal medicine and dialysis medicine. Salmon Pharma is the Swiss subsidiary of MEDICE.

We are specialized in processes optimization and validation, GMP and ISO compliance aspects, quality systems, risk analysis, CE marking, equipment qualification, project management, etc.

Azafaros is a clinical-stage biotech company addressing rare genetic lysosomal storage disorders with oral small molecules, including nizubaglustat. Our focus is on developing disease-modifying therapies for patients with, among others, GM1 and GM2 gangliosidoses, and Niemann-Pick Type C disease.

AlphaMol is an AI-based bio-pharmaceutical company focusing on G protein-coupled receptor drug discovery. The Cofounders of AlphaMol are leading scientists in the area of GPCRs. Many essential molecular mechanisms and biotechnology were invented by the members of AlphaMol.

Founded in 2018, Peptone specializes in novel therapeutics for Intrinsically Disordered Proteins (IDPs), linked to inflammatory diseases such as cancer. Their approach integrates biophysics, supercomputing, and machine learning, now advancing in their labs.

We are a clinical-stage biotech company developing first-in-class small molecules to induce mitophagy, i.e. the process of replacing damaged mitochondria. We address age-related and chronic diseases including CNS disorders to treat cognitive impairment..

Mosanna is committed to improving patient outcomes and quality of life in high unmet need diseases, carefully selecting innovative medicines for further development. Our first goal is to bring an effective and well tolerated medicinal nasal spray to Metabolic Obstructive Sleep Apnea patients.

Aukera builds a discovery engine that allows designing new classes of drugs to selectively target different branches of the mTOR pathway. The lead program selectively targets mTOR complex 1 to treat rare diseases, cancer, and neurodegenerative diseases, and uniquely addresses unmet medical needs.

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation.

Praed Pharmaceuticals is biopharmaceutical company founded by industry experts. Our mission is to deliver a next generation treatment for Crohn’s disease. We are developing a promising oral compound, cadazolid, for the treatment of Crohn’s disease.

Lucerna Chem is one of the leading distributors for life science products in Switzerland, providing high quality reagents and kits from more than 70 suppliers for both research and diagnostics. We conveniently supply our customers with a variety of 4 Mio. products in simple domestic shipments.

Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target scalable low COGS products, based on genetically engineered lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers - Cancers - Ovarian, Peritoneal

Based in Epalinges, Pilatus Biosciences focuses on developing a first-in-class antibody targeting metabolic checkpoints. The company is transforming cancer treatment by developing innovative therapies that strengthen the immune system to fight cancer.

CROss Alliance® is a Swiss CRO specialised in early clinical development. With more than 500 trials performed at CROSS phase I unit or in selected EU sites, we are experts in PK, bioequivalence, first in man, tolerability studies including cardiac safety and efficacy models in healthy volunteers.

Atopia Therapeutics is developing a revolutionary treatment for allergic diseases such as atopic dermatitis, allergic asthma, food allergies and hay fever based on the discovery that a bacterium present in the human stomach produces a protein that protects us from these diseases.

therainnova AG provides strategic and operational regulatory affairs consulting for the biopharmaceutical industry in Europe. With expert leadership and a strong partner network, we offer end-to-end regulatory support, including due diligence, to maximize portfolio value.

Limula is a Life Science Tools company based in Lausanne, Switzerland. We combine cell therapy process development and precision engineering to offer a fully closed and automated platform for the production of CAR-T and other highly-personalised treatments.

Bright Peak Therapeutics is a biotechnology company advancing a portfolio of multifunctional immunotherapies. We leverage our world-class protein engineering & conjugation platform to generate novel protein therapeutics for cancer and other indications. Bright Peak is located in Basel and San Diego.

Athebio develops ultra-stable biotherapeutics using proprietary Athebody® DARPin molecules with high affinity and specificity. We partner on radiotherapeutics, T cell engagers, targeted delivery (LNP/AAV/oligo) and affinity ligands, enabling breakthrough therapeutic strategies.

Vaderis Therapeutics AG is a clinical stage biotech focussing on treatment of rare diseases caused by vascular malformations. The company was founded in 2019 in Basel, Switzerland, and closed a Series A investment of CHF 18.1 Mio in 2020.

Novochizol SA researches and develops applications of Novochizol, a unique chitosan nanoparticle technology that yields different carriers of small molecules, peptides, nucleic acids and proteins for sustained, localized delivery to any living tissue, with intracellular targeting potential.

Rhizen is Swiss HQ biotech focused on discovery & development of innovative, small molecule drugs for the treatment of cancer & inflammatory diseases. The company has demonstrated leadership of the PI3K space and has a deep pipeline of novel differentiated assets across various stages of development.

GlycoEra is developing biologics to selectively degrade autoimmune disease causing circulating proteins rapidly, selectively, and deeply while avoiding broader dampening of the immune system. This offers many potential benefits over existing broad-spectrum immune-suppressing therapies.

Our foundation supports the transfer of innovation from medical research to industry, in particular through young entrepreneurship in Switzerland. We invest in companies in Switzerland or abroad that are active in the field of life sciences. We value strong founding teams and high-quality science.

MUVON is a Swiss, clinical stage biotech company with the goal of revolutionizing the treatment of diseases caused by muscle damage or degradation through the use of the patients' own cells. Our initial area of focus is the treatment of stress urinary incontinence in women (PhII completed)

Parexel is focused on the development of innovative new therapies to improve the world’s health. We do this by providing a suite of groundbreaking biopharmaceutical development services that help customers across the globe transform scientific discoveries into new treatments for patients. From clinical tria

Centenara is an integrated biotechnology platform company that develops and improves therapies and technologies to promote healthy aging and prolong lifespan. We provide start-up coaching and funding to entrepreneurial scientists to co-create therapies that benefit our aging population.

Alentis Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications. We are rapidly advancing our pipeline of antibodies and antibody-drug conjugates through clinical development.

OM Pharma is a global Geneva-based biopharmaceutical company. It is a leader in the prevention of recurrent respiratory and urinary tract infections, also active in the treatment of vascular diseases.

SOTIO is a biotech company building a diverse portfolio of oncology products through its own R&D, collaborations, in-licensing, investments, M&A. SOTIO is conducting multiple Phase I to III clinical trials targeting various types of cancer and has facilities in Europe and the US.

Synendos is a clinical stage neuroscience company developing potentially breakthrough safe and effective therapies for neuropsychiatric and neurological disorders through the modulation of a new drug target in the endocannabinoid system enabling restoration of the natural functioning of the brain

Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug development, drug manufacturing and digital health investment.

Clinical-stage biotech company developing next-generation allosteric therapies. Its candidate, GT-02287, is in P1b trials for PD with potential in other neurodegenerative and lysosomal storage disorders. The pipeline also includes preclinical programs targeting metabolic diseases and solid tumors.

Selective mode antimicrobial resistance therapeutics Selmod is a startup with a mission dedicated to the development of disruptive antibacterial and antifungal therapies needed to address the critical unmet need for antimicrobial resistance. Focus on high revenue segment - patients in hospitals.

Swiss-based Life Sciences consultancy and part of the athagoras Group. We enable European market access for pharma & biotech, combining strategy, evidence generation and HTA expertise, from valuation and trial design to reimbursement, JSC, JCA and pricing negotiations.

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need.

Regen Lab is a global leader in products for autologous regenerative medicine based on freshly prepared platelet rich plasma from the patient’s own blood, used either alone or combination with hyaluronic acid or other fresh autologous cells from the patient’s fat or bone marrow.

Oculis is a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic conditions with significant unmet medical needs. Headquartered in Switzerland, Oculis is led by an experienced management team and supported by leading international healthcare investors.

Nouscom is a privately held oncology company developing next-generation immunotherapies. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

Novassay is a biotech active in the area of Ion Channel therapeutics with focus in neuropathic pain and Oncology. We have a portfolio of assets currently in development (approaching IND stage) and interested in partnering and R&D collaborations.

Novimmune SA has brought 7 monoclonal antibodies to clinical development stage, one of which, Emapalumab, has been approved by the FDA in 2018. We now focus on our bispecific technology to build a pipeline of multispecific antibodies under the brand Light Chain Bioscience.

MetrioPharm AG, a clinical stage biopharmaceutical development company based in Zurich with a subsidiary in Berlin, Germany, has developed a platform of small molecule drug candidates (oral and i.v.) which targets the modulation of immune cell metabolism without suppressing the immune system.

Microsphere (MS) is a CDMO focused on new developments, cGMP manufacturing, R&D, analytical and regulatory support. MS is able to address complex challenges, including formulations for poorly water-soluble drugs, considering the extensive expertise in Spray Drying and Capsule Filling.

Memo Therapeutics AG develops therapeutic antibodies for viral infections and cancer. Lead asset potravitug targets BKV in kidney transplant recipients; Phase II SAFE KIDNEY data, presented in Nov 2025, support a planned Phase III start in 2026. MTx is also building an oncology discovery pipeline.

Legacy Healthcare aims to develop novel drugs for autoimmune, inflammatory and aging-related conditions, safe enough for chronic use especially by fragile populations, e.g. children, cancer patients and the elderly, who may be already on multiple medications.

Kinematica is a mechanical engineering company from Lucerne. We have our expertise in the field of homogenization and dispersion equipment form lab to production scale. We focus on close collaboration with our customer to built and scale equipment on request - for homogenization perfected.

Laves-Arzneimittel GmbH has focused on the exploration and development of preparations based on the probiotic Escherichia coli strain Laves discovered in 1931 by Dr. Wolfgang Laves.

Based on the liposomal technology platform, InnoMedica has built a diversified pipeline with lead compounds in oncology and neurodegenerative diseases. Clinical trials for the treatment of breast cancer as well as Parkinson's disease are conducted in Swiss hospitals.

InterAx developed a unique drug discovery platform integrating biochemistry, cellular pathways mathematical modelling and AI to decode the cellular communication language. This novel approach enables the rapid and precise identification of differentiated effective and safe candidates.

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients.

ImmunOs Therapeutics AG is a biotechnology company focused on discovering and developing novel human immunomodulatory proteins for cancer with a specific role in innate immunity.

Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology and dermato-oncology.

Calliditas is a commercial stage biopharmaceutical company focused on novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. In 2021, Calliditas acquired Genkyotex, specializing company in NOX therapies, French & Swiss based.

Our R&D center for biologics in Switzerland has end-to-end capabilities to discover Novel Biological Entities (NBEs) and develop them from inception through to pre-clinical & clinical studies. It is also fully equipped to manufacture clinical trial-size batch materials.

EspeRare is an ethical non-profit biotech. It combines pharmaceutical know-how and philanthropic and public investments to bring to life treatments that have been abandoned by the pharmaceutical industry. EspeRare represents an affordable alternative to the high cost innovation of medicines.

CSL (ASX:CSL; USOTC:CSLLY) – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – is a global biotechnology leader that develops and delivers innovative lifesaving medicines, protects public health and helps people with life-threatening medical conditions live full lives.

We develop ADCs and radioligands, leveraging our conjugation platform. We create new treatments offering hope to patients that suffer from aggressive cancer with poor prognosis.

Catalent is the global leader in enabling pharma, cell & gene therapy and biopharma partners to optimize product development, launch, and full life-cycle supply for patients around the world. Catalent helps accelerate over 1,000 partner programs every year for partners of all sizes.

We at Bioengineering AG design and build customized equipment to improve bioproduction efficiency in biotech, novel food, and biopharma plants. Our engineering teams develop reliable bioreactors and fermenters, from lab scale to production, for clients worldwide. Trusted for over 50 years.

At Biogen, we develop, market and manufacture therapies for people living with serious neurological, autoimmune and rare diseases.

Baliopharm AG, is a biotechnology company focusing on the development of innovative therapeutics for the treatment of chronic liver diseases, immune mediated inflammatory diseases, as well as for cancer.

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) is a commercial-stage biopharmaceutical company headquartered in Switzerland. Basilea is committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections.

Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, including orphan tauopathies, Alzheimer’s and Parkinson’s disease.

Anaveon is a global clinical stage biopharmaceutical company that specializes in developing novel treatments for diseases with high unmet needs. Our team is driven to make this vision a reality: we are committed to transforming immunological insights into life-changing therapies.

ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs.

AC Immune SA is a clinical-stage biopharma that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and NeuroOrphan indications. The Company has two clinically validated technology platforms, SupraAntigen® and Morphomer®.

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders.